Secukinumab is a fully humanised therapeutic monoclonal antibody targeting interleukin-17A. It is licensed and funded for the treatment of several chronic inflammatory conditions, including plaque psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). This publication reviews the efficacy and safety of secukinumab for the treatment of PsO, PsA and axSpA. It includes key outcomes from a multinational real world study (SERENA), along with those of other real-world and observational studies, together with pivotal clinical trials supporting the use of secukinumab in clinical practice.
Please login below to download this issue (PDF)